Innovage Holding Corp. (NASDAQ: INNV) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.30 | Insider Own | - | Shs Outstand | 135.74M | Perf Week | -2.18% |
| Market Cap | 1.52B | Forward P/E | 23.70 | EPS next Y | 0.47 | Insider Trans | 0.00% | Shs Float | 21.28M | Perf Month | -6.34% |
| Enterprise Value | 1.48B | PEG | - | EPS next Q | 0.07 | Inst Own | - | Short Float | 0.74% | Perf Quarter | 34.98% |
| Income | -21.00M | P/S | 1.61 | EPS this Y | 240.31% | Inst Trans | - | Short Ratio | 2.92 | Perf Half Y | 102.34% |
| Sales | 946.00M | P/B | 5.89 | EPS next Y | 12.58% | ROA | -4.06% | Short Interest | 1.00M | Perf YTD | 116.38% |
| Book/sh | 1.91 | P/C | 10.97 | EPS next 5Y | 12.58% | ROE | -9.20% | 52W High | 12.21 -11.16% | Perf Year | 238.25% |
| Cash/sh | 1.02 | P/FCF | 39.67 | EPS past 3/5Y | - | ROIC | 10.17% | 52W Low | 3.02 258.79% | Perf 3Y | 56.41% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 6.90% 8.54% | Gross Margin | 20.75% | Volatility | 5.05% 5.45% | Perf 5Y | -32.23% |
| Dividend TTM | - | EV/Sales | 1.56 | EPS Y/Y TTM | -87.50% | Oper. Margin | 3.91% | ATR (14) | 0.62 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.03 | Sales Y/Y TTM | 23.82% | Profit Margin | -2.35% | RSI (14) | 51.87 | Recom | 3.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.03 | EPS Q/Q | 180.00% | SMA20 | -2.65% | Beta | 0.37 | Target Price | 6.80 |
| Payout | 0.00% | Debt/Eq | 0.38 | Sales Q/Q | 15.60% | SMA50 | 12.74% | Rel Volume | 0.96 | Prev Close | 11.23 |
| Employees | 2,440 | LT Debt/Eq | 0.33 | Earnings | Sep 08 | SMA200 | 48.53% | Avg Volume | 359.90K | Price | 10.85 |
| IPO Date | Mar 04, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 94.17% 4.97% | Net Debt/EBITDA | -0.39 | Volume | 346,927 | Change | -3.38% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Dec-17-24 | Downgrade | JP Morgan | Neutral → Underweight | |
| Feb-08-23 | Reiterated | JP Morgan | Neutral | $8.00 |
| Nov-23-22 | Reiterated | Goldman Sachs | Neutral | $8.00 |
| Nov-16-22 | Reiterated | Citigroup | Neutral | $8.00 |
| Sep-15-22 | Reiterated | Barclays | Equal Weight | $5.00 |
| May-16-22 | Downgrade | Baird | Outperform → Neutral | |
| Apr-20-22 | Downgrade | Piper Sandler | Neutral → Underweight | $5.00 |
| Dec-28-21 | Downgrade | Goldman Sachs | Buy → Neutral | |
| Dec-27-21 | Downgrade | Barclays | Overweight → Equal Weight | |
| Sep-29-21 | Downgrade | Citigroup | Buy → Neutral |
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. It serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 1989 and is headquartered in Denver, Colorado.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 946 | 854 | 764 | 688 | 699 | 638 | 567 | 466 | |
| Cost of Goods Sold Incl. D&A | 750 | 269 | 632 | 587 | 563 | 476 | 426 | 355 | |
| Gross Profit | 196 | 585 | 132 | 101 | 135 | 162 | 141 | 111 | |
| Selling, General and Administrative Excl. Other | 204 | 150 | 136 | 135 | 126 | 155 | 77 | 65 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -45 | 465 | 19 | 16 | 14 | -68 | 13 | 6 | |
| Operating Income | 37 | -30 | -23 | -49 | -4 | 75 | 51 | 40 | |
| Interest Expense | 4 | 5 | 4 | 2 | 3 | 17 | 15 | 10 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -53 | 0 | 5 | 0 | 0 | -93 | -1 | -5 | |
| Net Income Before Taxes | -21 | -34 | -22 | -51 | -7 | -35 | 36 | 25 | |
| Income Taxes | 1 | 1 | 1 | -7 | 1 | 10 | 10 | 6 | |
| Consolidated Net Income | -21 | -30 | -21 | -41 | -7 | -44 | 26 | 20 | |
| Net Income From Continuing Operations | -21 | -35 | -23 | -44 | -8 | -45 | 26 | 19 | |
| Net Income | -21 | -30 | -21 | -41 | -7 | -44 | 26 | 20 | |
| EPS (Recurring) | -0.30 | -0.22 | -0.16 | -0.30 | -0.05 | -0.33 | 0.20 | 0.15 | |
| EPS (Basic, Before Extraordinaries) | -0.30 | -0.22 | -0.16 | -0.30 | -0.05 | -0.33 | 0.20 | 0.15 | |
| EPS (Diluted) | -0.30 | -0.22 | -0.16 | -0.30 | -0.05 | -0.33 | 0.20 | 0.15 | |
| EBITDA | 4 | 3 | 1 | -34 | 9 | -6 | 62 | 46 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.56 | 0.58 | 0.88 | 1.48 | 0.85 | 4.54 | — | — | |
| Gross Margin | 20.72 | 68.50 | 17.28 | 14.68 | 19.31 | 25.39 | 24.87 | 23.82 | |
| Operating Margin | 3.91 | -3.51 | -3.01 | -7.12 | -0.57 | 11.76 | 8.99 | 8.58 | |
| Net Margin | -2.22 | -3.51 | -2.75 | -5.96 | -1.00 | -6.90 | 4.59 | 4.29 | |
| Shares Outstanding | 136 | 135 | 136 | 136 | 136 | 136 | 133 | 133 | |
| Market Capitalization | 1,476 | 498 | 675 | 1,020 | 596 | 2,898 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SCARBROUGH MICHAEL ANTHONY | President and COO | Nov 14 '25 | Sale | 4.90 | 33,000 | 161,700 | 119,617 | Nov 17 |
| ZORETIC RICHARD C | Director | May 30 '25 | Buy | 4.08 | 8,450 | 34,476 | 68,494 | May 30 |
| ZORETIC RICHARD C | Director | May 29 '25 | Buy | 4.04 | 14,265 | 57,631 | 60,044 | May 30 |
| ZORETIC RICHARD C | Director | May 28 '25 | Buy | 4.06 | 20,000 | 81,200 | 45,779 | May 30 |
| ZORETIC RICHARD C | Director | May 23 '25 | Buy | 3.93 | 1,198 | 4,708 | 25,779 | May 23 |
| ZORETIC RICHARD C | Director | May 22 '25 | Buy | 4.09 | 700 | 2,863 | 24,581 | May 23 |
| ZORETIC RICHARD C | Director | May 21 '25 | Buy | 4.13 | 1,147 | 4,737 | 23,881 | May 23 |
| ZORETIC RICHARD C | Director | May 20 '25 | Buy | 4.20 | 807 | 3,389 | 22,734 | May 20 |
| ZORETIC RICHARD C | Director | May 16 '25 | Buy | 4.28 | 2,086 | 8,928 | 21,927 | May 20 |
| SCARBROUGH MICHAEL ANTHONY | President and COO | May 13 '25 | Buy | 3.89 | 10,000 | 38,900 | 33,000 | May 13 |
| SCARBROUGH MICHAEL ANTHONY | President and COO | May 12 '25 | Buy | 3.73 | 13,000 | 48,490 | 23,000 | May 13 |
| SCARBROUGH MICHAEL ANTHONY | President and COO | May 09 '25 | Buy | 3.55 | 10,000 | 35,500 | 10,000 | May 13 |
| DAMATO NICOLE | CHIEF LEGAL OFFICER | Nov 06 '24 | Sale | 6.54 | 1,660 | 10,856 | 231,614 | Nov 08 |
| DAMATO NICOLE | Chief Legal Officer | Sep 17 '24 | Sale | 6.00 | 7,521 | 45,126 | 233,274 | Sep 18 |
| DAMATO NICOLE | Chief Legal Officer | Sep 16 '24 | Sale | 5.95 | 4,372 | 26,013 | 240,795 | Sep 18 |